Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study

Panichi, Vincenzo; Manca-Rizza, Giovanni; Paoletti, Sabrina; Taccola, D; Consani, Cristina; Sbragia, G.; Mantuano, Elide; Marchetti, Veronica; Carpi, Angelo; Barsotti, Giovanni

doi:10.1016/j.biopha.2006.04.004

Cited by 12 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies have investigated the efficacy and safety of ezetimibe in the kidney transplant population (34–37). Renal transplant recipients often have elevated cholesterol levels despite statin therapy (38,39) and as CVD is the primary cause of death in these patients (40,41), complementary lipid lowering treatment is often warranted.…”

Section: Effectiveness Of Ezetimibe In Clinical Trialsmentioning

confidence: 99%

“…Renal transplant recipients often have elevated cholesterol levels despite statin therapy (38,39) and as CVD is the primary cause of death in these patients (40,41), complementary lipid lowering treatment is often warranted. Ezetimibe has been proved an effective and safe treatment option for dyslipidaemia, both in combination with statins and as monotherapy, in this group of patients (34,37).…”

Section: Effectiveness Of Ezetimibe In Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

Ezetimibe-associated adverse effects: what the clinician needs to know

Florentin

Liberopoulos

Elisaf

2007

International Journal of Clinical Practice

View full text Add to dashboard Cite

Ezetimibe is a safe alternative option for hyperlipidaemic patients intolerant to other lipid lowering drugs as well as a beneficial supplementary agent for patients who do not reach the recommended serum cholesterol level with their current hypolipidaemic treatment. However, as is the case with all new medications, physicians should be alert to recognise adverse effects associated with ezetimibe and report them to regulatory authorities.

show abstract

Section: Effectiveness Of Ezetimibe In Clinical Trialsmentioning

confidence: 99%

Section: Effectiveness Of Ezetimibe In Clinical Trialsmentioning

confidence: 99%

Ezetimibe-associated adverse effects: what the clinician needs to know

Florentin

Liberopoulos

Elisaf

2007

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Additionally, ezetimibe/ simvastatin 40 mg/d resulted in greater reduction in CRP compared with atorvastatin 20 mg/d [235]. Ezetimibe coadministered with atorvastatin in 5 renal transplant patients significantly reduced CRP levels (6.2 ± 1.0 to 3.9 ± 2.4 mg/l, p < 0.05) [292]. In contrast, no additional decrease in hsCRP was observed after ezetimibe was added to fenofibrate (n = 576) [258].…”

Section: V) Effects On Inflammatory Markersmentioning

confidence: 90%

Lipid-Lowering Drugs Acting at the Level of the Gastrointestinal Tract

Filippatos

Mikhailidis²

2009

CPD

View full text Add to dashboard Cite

This review considers the hypolipidaemic drugs that act on the gastrointestinal (GI) tract. We searched PubMed up to April 2008 and included randomized controlled trials, original papers, review articles and case reports. Bile acid sequestrants (BAS) have a well-established low density lipoprotein cholesterol (LDL-C) lowering effect, but may increase triglyceride (TG) levels. BAS have no systematic adverse effects, but are associated with increased GI adverse effects and interactions with the absorption of other drugs. Ezetimibe improves LDL-C, high density lipoprotein cholesterol and TG levels, as monotherapy or especially when given with a statin. Ezetimibe has not been associated with serious adverse effects. Ezetimibe has not been evaluated in large clinical trials with cardiovascular disease (CVD) endpoints. Phytosterols are not licensed drugs; they have a well-established LDL-C lowering effect, but there are no large long-term randomized clinical trials investigating their effects on CVD events. Orlistat is an antiobesity drug with a small additional LDL-C lowering effect independent of weight loss. Orlistat-assisted weight loss improves the overall lipid profile, carbohydrate metabolism and transaminase activities. However, its use should be limited to weight reduction. This drug is associated with increased GI adverse effects.

show abstract

“…Data on the use of ezetimibe in other types of transplant recipients, mainly renal transplant patients, also suggest that the combination of ezetimibe and statins is safe. 12-18…”

Section: Discussionmentioning

confidence: 99%